Cross-Border Impact Ventures Announces US$58 Million First Close of Women’s and Children’s Health Technology Fund II
Second fund builds on successful portfolio, strategic exit, and measurable global health impact as institutional investors double down on women’s and children’s health innovation
Cross-Border Impact Ventures (CBIV) today announced the first close of its second fund, the Women’s and Children’s Health Technology Fund II, securing US$58 million toward a target fund size of US$125 million. The new fund has attracted commitments from both returning and new institutional investors, reflecting continued confidence in CBIV’s investment strategy, team, and track record. LPs in the new fund include returning investors who doubled down, including KfW on behalf of German Federal Ministry for Economic Cooperation and Development (BMZ), the Skoll Foundation with its OCIO – Capricorn Investment Group, Ceniarth, Equality Fund with its OCIO – RockCreek Group, Wire Group, and several family offices and high-net-worth individuals, among others. CBIV expects to complete the final close of Fund II in 2027.
CBIV invests in companies developing technologies that address conditions affecting women and children specifically, differently or disproportionately at the Series A or B stage. CBIV’s inaugural US$90.3 million Fund I invested in 11 technology companies spanning maternal and fetal health, neonatal care, cardiovascular disease, oncology, respiratory health, reproductive health and gut health. Fund I had a successful strategic exit and helped the portfolio reach more than 356,000 women and children across 32 countries.
